Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Dow
Cipla
Citi
Healthtrust
McKinsey
Moodys
Federal Trade Commission
Merck

Generated: April 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,022,022

« Back to Dashboard

Which drugs does patent 9,022,022 protect, and when does it expire?

Patent 9,022,022 protects EVZIO and is included in two NDAs.

This patent has thirty-two patent family members in ten countries.
Summary for Patent: 9,022,022
Title:Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Abstract: Medicament delivery devices for administration of opioid antagonists are described herein. In some embodiments, an apparatus includes a housing, a medicament container disposed within the housing and an energy storage member disposed within the housing. The medicament container is filled with a naloxone composition that includes naloxone or salts thereof, a tonicity-adjusting agent, and a pH adjusting agent, whereby the osmolality of the naloxone composition ranges from about 250-350 mOsm and the pH ranges from about 3-5. The energy storage member is configured to produce a force to deliver the naloxone composition.
Inventor(s): Edwards; Eric S. (Moseley, VA), Edwards; Evan T. (Charlottesville, VA), Licata; Mark J. (Doswell, VA), Blondino; Frank E. (Henrico, VA)
Assignee: kaleo, Inc. (Richmond, VA)
Application Number:14/153,575
Patent Claim Types:
see list of patent claims
Composition; Device; Delivery;

Drugs Protected by US Patent 9,022,022

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Kaleo Inc EVZIO naloxone hydrochloride SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 205787-001 Apr 3, 2014 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Kaleo Inc EVZIO naloxone hydrochloride SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 209862-001 Oct 19, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,022,022

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,084,849 Medicament delivery devices for administration of a medicament within a prefilled syringe ➤ Try a Free Trial
9,173,999 Devices and methods for delivering medicaments from a multi-chamber container ➤ Try a Free Trial
8,627,816 Medicament delivery device for administration of opioid antagonists including formulations for naloxone ➤ Try a Free Trial
9,814,838 Medicament delivery device for administration of opioid antagonists including formulations for naloxone ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,022,022

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011218756 ➤ Try a Free Trial
Australia 2012211307 ➤ Try a Free Trial
Australia 2012211320 ➤ Try a Free Trial
Brazil 112013018917 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Argus Health
Cipla
Medtronic
Daiichi Sankyo
Deloitte
Citi
Fuji
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.